Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting (Q42930829)

11 November 2017

title

Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting (English)

1 reference

11 November 2017

Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

20 June 2024

0 references

Annette Wundes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727669

20 June 2024

George H. Kraft

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727669

20 June 2024

James D. Bowen

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727669

20 June 2024

Ted A. Gooley

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727669

20 June 2024

Richard A. Nash

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727669

20 June 2024

language of work or name

1 reference

19 August 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S0303846710002325?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

https://api.elsevier.com/content/article/PII:S0303846710002325?httpAccept=text/plain

20 June 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Clinical Neurology and Neurosurgery

20 June 2024

published in

1 reference

11 November 2017

volume

112

1 reference

11 November 2017

1 reference

11 November 2017

page(s)

876-882

1 reference

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Secondary progressive multiple sclerosis: current knowledge and future challenges

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

New natural history of interferon-β-treated relapsing multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Management of worsening multiple sclerosis with mitoxantrone: a review

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Mitoxantrone for multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Therapeutic role of mitoxantrone in multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Severe heart failure in a young multiple sclerosis patient

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Acute myeloid leukaemia induced by mitoxantrone: case report

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Immunosuppression followed by immunomodulation

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Long-term experience with induction treatment regimens in multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINEURO.2010.07.018

20 June 2024

Identifiers

1 reference

11 November 2017

1 reference